Immunogenicity and Safety Assessment of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine (Abdala) in Paediatric Ages 3 to 18 Years Old: A Double-Blinded, Multicentre, Randomised, Phase 1/2 Clinical Trial (ISMAELILLO Study)

A Review of COVID-19 Vaccines, Immunogenicity, Safety, and Efficacy Toward Addressing Vaccine Hesitancy, Inequity, and Future Epidemic Preparedness

“…Abdala vaccine was safe, encompassing a diverse range of participants spanning from 3 to 80 years old [22,23]. Most adverse reactions to the vaccine were mild and localized to the injection site, resolving within 24-48 hours.…”

“…Overall, these findings suggest that Covovax has the potential to be an effective booster dose, providing enhanced immune protection to individuals who have previously received different priming dose regimens.The Abdala vaccine is found to induce substantial humoral immune responses against SARS-CoV-2 among adults 19-80 years of age after third dose of vaccination[22]. In addition, Abdala vaccine also stimulated the production of specific IgG antibodies against the RBD of SARS-CoV-2, as well as ACE2 inhibition titers and neutralizing antibodies in healthy children and adolescents with age (3-11 years, or 12-18 years old)[23].…”